Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis

Current Pharmaceutical Design

Volumn 10, Issue 26, 2004, Pages 3239-3262

  Barry III, Clifton E ^a   Boshoff, Helena I M ^a   Dowd, Cynthia S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Anaerobic metabolism; Bioreduction; Metronidazole; Mutagenicity; Mycobacterium tuberculosis; Nitroimidazole; Nitroreductase; Persistence

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; BENZNIDAZOLE; BENZOFURAN DERIVATIVE; CARNIDAZOLE; CGI 17341; DIMETRIDAZOLE; FURAN DERIVATIVE; ISONIAZID; METRONIDAZOLE; MISONIDAZOLE; NIFURTIMOX; NIMORAZOLE; NIRIDAZOLE; NITROIMIDAZOLE DERIVATIVE; ORNIDAZOLE; PA 1282; PA 1324; PA 1327; PA 1328; PA 1343; PA 636; PA 647; PA 653; PANIDAZOLE; RIFAMPICIN; SATRANIDAZOLE; SECNIDAZOLE; TINIDAZOLE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANOREXIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ATAXIA; CARCINOGENICITY; CROHN DISEASE; DEPRESSION; DIZZINESS; DRUG ABSORPTION; DRUG ALCOHOL INTERACTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED CANCER; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG TOLERABILITY; EMBRYOTOXICITY; GASTROINTESTINAL SYMPTOM; GENOTOXICITY; HEADACHE; HUMAN; IN VIVO STUDY; MUTAGENICITY; MYCOBACTERIUM AVIUM; MYCOBACTERIUM BOVIS; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM GORDONAE; MYCOBACTERIUM INTRACELLULARE; MYCOBACTERIUM KANSASII; MYCOBACTERIUM SCROFULACEUM; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NONHUMAN; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SEIZURE; SPERMATOZOON ABNORMALITY; STRUCTURE ACTIVITY RELATION; TASTE DISORDER; TERATOGENICITY; TONGUE DISEASE; TUBERCULOSIS; VOMITING;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; DRUG EVALUATION, PRECLINICAL; HUMANS; NITROIMIDAZOLES; RANDOMIZED CONTROLLED TRIALS; SINGLE-BLIND METHOD; TUBERCULOSIS, PULMONARY;

EID: 4644371358     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043383214     Document Type: Review

References (178)

1. Raether W, Hanel H. Nitroheterocyclic drugs with broad spectrum activity. Parasitol Res 2003; 90 Supp 1: S19-39.
2. Voogd CE. On the mutagenicity of nitroimidazoles. Mutat Res 1981; 86: 243-77.
3. Bendesky A, Menendez D, Ostrosky-Wegman P. Is metronidazole carcinogenic? Mutat Res 2002; 511: 133-44.
4. Roe FJ. Metronidazole: review of uses and toxicity. J Antimicrob Chemother 1977; 3: 205-12.
5. Roe VA. Antimicrobial agents: pharmacology and clinical application in obstetric, gynecologic, and perinatal infections. J Obstet Gynecol Neonatal Nurs 1999; 28: 639-48.
6. Schneider J. Treatment of giardiasis (lambliasis) by metronidazole. Bull Soc Pathol Exot Filiales 1961; 54: 84-95.
7. Rodriques Coura J, de Castro SL. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 2002; 97: 3-24.
8. Veldhuyzen van Zanten SJ, Sherman PM, Hunt RH. Helicobacter pylori: new developments and treatments. Cmaj 1997; 156: 1565-74.
9. Slots J. Selection of antimicrobial agents in periodontal therapy. J Periodontal Res 2002; 37: 389-98.
10. Adams GE, Stratford IJ, Bremner JC, Edwards HS, Fielden EM. Nitroheterocyclic compounds as radiation sensitizers and bioreductive drugs. Radiother Oncol 1991; 20 Suppl 1: 85-91.
11. Voogd CE. Azathioprine, a genotoxic agent to be considered non-genotoxic in man. Mutat Res 1989; 221: 133-52.
12. Voogd CE, Van der Stel JJ, Jacobs JJ. The mutagenic action of nitroimidazoles. I. Metronidazole, nimorazole, dimetridazole and ronidazole. Mutat Res 1974; 26: 483-90.
13. Hite M, Skeggs H, Noveroske J, Peck H. Mutagenic evaluation of ronidazole. Mutat Res 1976; 40: 289-304.
14. Lamp KC, Freeman CD, Klutman NE, Lacy MK. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet 1999; 36: 353-73.
15. Freeman CD, Klutman NE, Lamp KC. Metronidazole. A therapeutic review and update. Drugs 1997; 54: 679-708.
16. Carmine AA, Brogden RN, Heel RC, Speight TM, Avery GS. Tinidazole in anaerobic infections: a review of its antibacterial activity, pharmacological properties and therapeutic efficacy. Drugs 1982; 24: 85-117.
17. Lau AH, Lam NP, Piscitelli SC, Wilkes L, Danziger LH. Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives. Clin Pharmacokinet 1992; 23: 328-64.
18. Cavalleri B. In: Breccia A, Cavalleri B, Adams GE. Eds, Nitroimidazoles: Chemistry, Pharmacology, and Clinical Application. New York and London, Plenum Press. 1982; 9-33.
19. Hof H. Antibacterial activities of the antiparasitic drugs nifurtimox and benznidazole. Antimicrob Agents Chemother 1989; 33: 404-5.
20. Hof H, Stroder J, Buisson JP, Royer R. Effect of different nitroheterocyclic compounds on aerobic, microaerophilic, and anaerobic bacteria. Antimicrob Agents Chemother 1986; 30: 679-83.
21. Jones BM, Geary I, Lee ME, Duerden BI. Comparison of the in vitro activities of fenticonazole, other imidazoles, metronidazole, and tetracycline against organisms associated with bacterial vaginosis and skin infections. Antimicrob Agents Chemother 1989; 33: 970-2.
22. Olsson-Liljequist B, Nord CE. In vitro susceptibility of anaerobic bacteria to nitroimidazoles. Scand J Infect Dis Suppl 1981; 26: 42-5.
23. Jokipii L, Jokipii AM. Comparative evaluation of the 2-methyl-5-nitroimidazole compounds dimetridazole, metronidazole, secnidazole, ornidazole, tinidazole, carnidazole, and panidazole against Bacteroides fragilis and other bacteria of the Bacteroides fragilis group. Antimicrob Agents Chemother 1985; 28: 561-4.
24. Hof H, Stroder J. Antibacterial activity of GO 10213, a nitroimidazole derivative. Antimicrob Agents Chemother 1986; 29: 953-4.
25. Shafiee A, Sayadi A, Roozbahani MH, Foroumadi A, Kamal F. Synthesis and in vitro antimicrobial evaluation of 5-(1-methyl-5-nitro-2-imidazolyl)-4H-1, 2, 4-triazoles. Arch Pharm (Weinheim) 2002; 335: 495-9.
26. Cavalleri B, Ballotta R, Arioli V, Lancini G. New 5-substituted 1-alkyl-2-nitroimidazoles. J Med Chem 1973; 16: 557-60.
27. Cavalleri B, Volpe G, Arioli V. Synthesis and biological activity of some vinyl-substituted 2-nitroimidazoles. J Med Chem 1977; 20: 656-60.
28. Cavalleri B, Volpe G, Arioli V, Parenti F. Synthesis and biological activity of some 2-aminoimidazoles. Arzneimittelforschung 1977; 27: 1889-95.
29. Cavalleri B, Volpe G, Ripamonti A, Arioli V. 1-Methyl-2-nitroimidazol-5-yl derivatives. IIIrd communication. Arzneimittelforschung 1977; 27: 1131-34.
30. Cavalleri B, Volpe G, Arioli V, Lancini GC. 1-Methyl-2-nitroimidazol-5-yl derivatives. IVth Communication. Arzneimittelforschung 1977; 27: 1391-2.
31. Sehgal RK, Agrawal KC. Novel Nitroimidazo[2,1-b] oxazole Formation from Reaction of 2, 4(5)-Dinitroimidazole with Oxiranes (1). J Heterocyclic Chem 1979; 16: 1499-1500.
32. Nagarajan K, Shankar RG, Rajappa S, Shenoy SJ, Costa-Pereira R. Nitroimidazoles XXI. 2, 3-dihydro-6-nitroimidazo[2,1-b]oxazoles with antitubercular activity. Eur J Med Chem 1989; 24: 631-633.
33. Ashtekar DR, Costa-Perira R, Nagrajan K, Vishvanathan N, Bhatt AD, Rittel W. In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1993; 37: 183-6.
34. Baker WR, Shaopei C, Keeler EL. Nitroimidazole antibacterial compounds and methods of use thereof. US Patent 5, 668, 127; 1997.
35. Baker WR, Shaopei C, Keeler EL. Nitro-[2,1-B]imidazopyran compounds and antibacterial uses thereof. US patent 6, 087, 358; 2000.
36. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000; 405: 962-6.
37. Arain TM, Resconi AE, Hickey MJ, Stover CK. Bioluminescence screening in vitro (Bio-Siv) assays for high-volume antimycobacterial drug discovery. Antimicrob Agents Chemother 1996; 40: 1536-41.
38. Arain TM, Resconi AE, Singh DC, Stover CK. Reporter gene technology to assess activity of antimycobacterial agents in macrophages. Antimicrob Agents Chemother 1996; 40: 1542-4.
39. Stead WW. Pathogenesis of the sporadic case of tuberculosis. N Engl J Med 1967; 277: 1008-12.
40. Stead WW. Pathogenesis of a first episode of chronic pulmonary tuberculosis in man: recrudescence of residuals of the primary infection or exogenous reinfection? Am Rev Respir Dis 1967; 95: 729-45.
41. Saunders BM, Cooper AM. Restraining mycobacteria: role of granulomas in mycobacterial infections. Immunol Cell Biol 2000; 78: 334-41.
42. Raupach B, Kaufmann SH. Immune responses to intracellular bacteria. Curr Opin Immunol 2001; 13: 417-28.
43. Salkin D, Wayne LG. The bacteriology of resected tuberculous pulmonary lesions. I. The effect of interval between reversal of infectiousness and subsequent surgery. Am Rev Tuberc 1956; 74: 376-87.
44. Opie EL, Aronson JD. Tubercle bacilli in latent tuberculous lesions and in lung tissue without tuberculous lesions. Arch Path Lab Med 1927; 4: 1.
45. Mitchison DA. Basic mechanisms of chemotherapy. Chest 1979; 76: 771-81.
46. Handwerger S, Tomasz A. Antibiotic tolerance among clinical isolates of bacteria. Rev Infect Dis 1985; 7: 368-86.
47. Wayne LG, Hayes LG. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 1996; 64: 2062-9.
48. Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980; 121: 939-49.
49. Jindani A, Dore CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 2003; 167: 1348-54.
50. Loring WE, Vandiviere HM. The treated pulmonary lesion and its tubercle bacillus. I. Pathology and pathogenesis. Am J Med Sci 1956; 232: 20-9.
51. Vandiviere HM, Loring WE, Melvin I, Willis S. The treated pulmonary lesion and its tubercle bacillus. II. The death and resurrection. Am J Med Sci 1956; 232: 30-7.
52. Cynamon MH, Sklaney M. Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis. Antimicrob Agents Chemother 2003; 47: 2442-4.
53. Lenaerts AJ, Gruppo V, Brooks JV, Orme IM. Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice. Antimicrob Agents Chemother 2003; 47: 783-5.
54. Yoshimatsu T, Nuermberger E, Tyagi S, Chaisson R, Bishai W, Grosset J. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrob Agents Chemother 2002; 46: 1875-9.
55. Wayne LG, Sramek HA. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1994; 38: 2054-8.
56. McCune RM Jr, Tompsett R. Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. I. The persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy. J Exp Med 1956; 104: 737-62.
57. McCune RM Jr, McDermott W, Tompsett R. The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J Exp Med 1956; 104: 763-802.
58. Scanga CA, Mohan VP, Joseph H, Yu K, Chan J, Flynn JL. Reactivation of latent tuberculosis: variations on the Cornell murine model. Infect Immun 1999; 67: 4531-8.
59. Boon C, Li R, Qi R, Dick T. Proteins of Mycobacterium bovis BCG induced in the Wayne dormancy model. J Bacteriol 2001; 183: 2672-6.
60. Wayne LG, Hayes LG. Nitrate reduction as a marker for hypoxic shiftdown of Mycobacterium tuberculosis. Tuber Lung Dis 1998; 79: 127-32.
61. Sherman DR, Voskuil M, Schnappinger D, Liao R, Harrell MI, Schoolnik GK. Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha -crystallin. Proc Natl Acad Sci USA 2001; 98: 7534-9.
62. Schnappinger D, Ehrt S, Voskuil MI, Liu Y, Mangan JA, Monahan IM, et al. Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages: Insights into the Phagosomal Environment. J Exp Med 2003; 198: 693-704.
63. Voskuil MI, Schnappinger D, Visconti KC, Harrell MI, Dolganov GM, Sherman DR, et al. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med 2003; 198: 705-13.
64. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 2002; 43: 717-31.
65. Ouellet H, Ouellet Y, Richard C, Labarre M, Wittenberg B, Wittenberg J, et al. Truncated hemoglobin HbN protects Mycobacterium bovis from nitric oxide. Proc Natl Acad Sci USA 2002; 99: 5902-7.
66. Dahl JL, Kraus CN, Boshoff HI, Doan B, Foley K, Avarbock D, et al. The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice. Proc Natl Acad Sci USA 2003; 100: 10026-31.
67. McKinney JD. In vivo veritas: the search for TB drug targets goes live. Nat Med 2000; 6: 1330-3.
68. Hingley-Wilson SM, Sambandamurthy VK, Jacobs WR, Jr. Survival perspectives from the world's most successful pathogen, Mycobacterium tuberculosis. Nat Immunol 2003; 4: 949-55.
69. Sun Z, Zhang Y. Antituberculosis activity of certain antifungal and antihelmintic drugs. Tuber Lung Dis 1999; 79: 319-20.
70. Brooks JV, Furney SK, Orme IM. Metronidazole therapy in mice infected with tuberculosis. Antimicrob Agents Chemother 1999; 43: 1285-8.
71. Dhillon J, Allen BW, Hu YM, Coates AR, Mitchison DA. Metronidazole has no antibacterial effect in Cornell model murine tuberculosis. Int J Tuberc Lung Dis 1998; 2: 736-42.
72. Paramasivan CN, Kubendiran G, Herbert D. Action of metronidazole in combination with isoniazid & rifampicin on persisting organisms in experimental murine tuberculosis. Indian J Med Res 1998; 108: 115-9.
73. Desai CR, Heera S, Patel A, Babrekar AB, Mahashur AA, Kamat SR. Role of metronidazole in improving response and specific drug sensitivity in advanced pulmonary tuberculosis. J Assoc Physicians India 1989; 37: 694-7.
74. Carvalho E, Francisco AP, Iley J, Rosa E. Triazene drug metabolites. Part 17: Synthesis and plasma hydrolysis of acyloxymethyl carbamate derivatives of antitumour triazenes. Bioorg Med Chem 2000; 8: 1719-25.
75. Schmid A, Schmid H. Pharmaco-toxicological mode of action of antimicrobial 5-nitroimidazole derivatives. Zentralbl Veterinarmed A 1999; 46: 517-22.
76. Edwards DI. Nitroimidazole drugs-action and resistance mechanisms. I. Mechanisms of action. J Antimicrob Chemother 1993; 31: 9-20.
77. Ehlhardt WJ, Beaulieu BB Jr, Goldman P. Nitrosoimidazoles: highly bactericidal analogues of 5-nitroimidazole drugs. J Med Chem 1988; 31: 323-9.
78. Ehlhardt WJ, Beaulieu BB Jr, Goldman P. Formation of an amino reduction product of metronidazole in bacterial cultures: lack of bactericidal activity. Biochem Pharmacol 1987; 36: 259-64.
79. Ehlhardt WJ, Beaulieu BB Jr, Goldman P. Chemical and biological properties of acetyl derivatives of the hydroxylamino reduction products of metronidazole and dimetridazole. Biochem Pharmacol 1987; 36: 931-5.
80. Ehlhardt WJ, Beaulieu BB Jr, Goldman P. Mammalian cell toxicity and bacterial mutagenicity of nitrosoimidazoles. Biochem Pharmacol 1988; 37: 2603-6.
81. Sisson G, Jeong JY, Goodwin A, Bryden L, Rossler N, Lim-Morrison S, et al. Metronidazole activation is mutagenic and causes DNA fragmentation in Helicobacter pylori and in Escherichia coli containing a cloned H. pylori RdxA(+) (Nitroreductase) gene. J Bacteriol 2000; 182: 5091-6.
82. Yeung TC, Beaulieu BB Jr, McLafferty MA, Goldman P. Interaction of metronidazole with DNA repair mutants of Escherichia coli. Antimicrob Agents Chemother 1984; 25: 65-70.
83. Thompson SA, Blaser MJ. Isolation of the Helicobacter pylori recA gene and involvement of the recA region in resistance to low pH. Infect Immun 1995; 63: 2185-93.
84. Samuelson J. Why metronidazole is active against both bacteria and parasites. Antimicrob Agents Chemother 1999; 43: 1533-41.
85. Kulda J. Trichomonads, hydrogenosomes and drug resistance. Int J Parasitol 1999; 29: 199-212.
86. Edwards DI. Nitroimidazole drugs-action and resistance mechanisms. II. Mechanisms of resistance. J Antimicrob Chemother 1993; 31: 201-10.
87. Ragsdale SW. Pyruvate ferredoxin oxidoreductase and its radical intermediate. Chem Rev 2003; 103: 2333-46.
88. Upcroft P, Upcroft JA. Drug targets and mechanisms of resistance in the anaerobic protozoa. Clin Microbiol Rev 2001; 14: 150-64.
89. Knodler LA, Sekyere EO, Stewart TS, Schofield PJ, Edwards MR. Cloning and expression of a prokaryotic enzyme, arginine deiminase, from a primitive eukaryote Giardia intestinalis. J Biol Chem 1998; 273: 4470-7.
90. Wassmann C, Hellberg A, Tannich E, Bruchhaus I. Metronidazole resistance in the protozoan parasite Entamoeba histolytica is associated with increased expression of iron-containing superoxide dismutase and peroxiredoxin and decreased expression of ferredoxin 1 and flavin reductase. J Biol Chem 1999; 274: 26051-6.
91. Lloyd D, Kristensen B. Metronidazole inhibition of hydrogen production in vivo in drug-sensitive and resistant strains of Trichomonas vaginalis. J Gen Microbiol 1985; 131 (Pt 4): 849-53.
92. Narcisi EM, Secor WE. In vitro effect of tinidazole and furazolidone on metronidazole-resistant Trichomonas vaginalis. Antimicrob Agents Chemother 1996; 40: 1121-5.
93. Land KM, Delgadillo MG, Johnson PJ. In vivo expression of ferredoxin in a drug resistant trichomonad increases metronidazole susceptibility. Mol Biochem Parasitol 2002; 121: 153-7.
94. Dunne RL, Dunn LA, Upcroft P, O'Donoghue PJ, Upcroft JA. Drug resistance in the sexually transmitted protozoan Trichomonas vaginalis. Cell Res 2003; 13: 239-49.
95. Kulda J, Tachezy J, Cerkasovova A. In vitro induced anaerobic resistance to metronidazole in Trichomonas vaginalis. J Eukaryot Microbiol 1993; 40: 262-9.
96. Borst P, Ouellette M. New mechanisms of drug resistance in parasitic protozoa. Annu Rev Microbiol 1995; 49: 427-60.
97. Smith MA, Edwards DI. Redox potential and oxygen concentration as factors in the susceptibility of Helicobacter pylori to nitroheterocyclic drugs. J Antimicrob Chemother 1995; 35: 751-64.
98. Smith MA, Edwards DI. Oxygen scavenging, NADH oxidase and metronidazole resistance in Helicobacter pylori. J Antimicrob Chemother 1997; 39: 347-53.
99. Hughes NJ, Chalk PA, Clayton CL, Kelly DJ. Identification of carboxylation enzymes and characterization of a novel four-subunit pyruvate: flavodoxin oxidoreductase from Helicobacter pylori. J Bacteriol 1995; 177: 3953-9.
100. Hughes NJ, Clayton CL, Chalk PA, Kelly DJ. Helicobacter pylori porCDAB and oorDABC genes encode distinct pyruvate: flavodoxin and 2-oxoglutarate: acceptor oxidoreductases which mediate electron transport to NADP. J Bacteriol 1998; 180: 1119-28.
101. Hoffman PS, Goodwin A, Johnsen J, Magee K, Veldhuyzen van Zanten SJ. Metabolic activities of metronidazole-sensitive and -resistant strains of Helicobacter pylori: repression of pyruvate oxidoreductase and expression of isocitrate lyase activity correlate with resistance. J Bacteriol 1996; 178: 4822-9.
102. Sisson G, Goodwin A, Raudonikiene A, Hughes NJ, Mukhopadhyay AK, Berg DE, et al. Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in Helicobacter pylori. Antimicrob Agents Chemother 2002; 46: 2116-23.
103. Kwon DH, Osato MS, Graham DY, El-Zaatari FA. Quantitative RT-PCR analysis of multiple genes encoding putative metronidazole nitroreductases from Helicobacter pylori. Int J Antimicrob Agents 2000; 15: 31-6.
104. Goodwin A, Kersulyte D, Sisson G, Veldhuyzen van Zanten SJ, Berg DE, Hoffman PS. Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase. Mol Microbiol 1998; 28: 383-93.
105. Mendz GL, Megraud F. Is the molecular basis of metronidazole resistance in microaerophilic organisms understood? Trends Microbiol 2002; 10: 370-5.
106. Bereswill S, Krainick C, Stahler F, Herrmann L, Kist M. Analysis of the rdxA gene in high-level metronidazole-resistant clinical isolates confirms a limited use of rdxA mutations as a marker for prediction of metronidazole resistance in Helicobacter pylori. FEMS Immunol Med Microbiol 2003; 36: 193-8.
107. Jeong JY, Mukhopadhyay AK, Dailidiene D, Wang Y, Velapatino B, Gilman RH, et al. Sequential inactivation of rdxA (HP0954) and frxA (HP0642) nitroreductase genes causes moderate and high-level metronidazole resistance in Helicobacter pylori. J Bacteriol 2000; 182: 5082-90.
108. Kwon DH, Hulten K, Kato M, Kim JJ, Lee M, El-Zaatari FA, et al. DNA sequence analysis of rdxA and frxA from 12 pairs of metronidazole-sensitive and -resistant clinical Helicobacter pylori isolates. Antimicrob Agents Chemother 2001; 45: 2609-15.
109. Rafii F, Wynne R, Heinze TM, Paine DD. Mechanism of metronidazole-resistance by isolates of nitroreductase-producing Enterococcus gallinarum and Enterococcus casseliflavus from the human intestinal tract. FEMS Microbiol Lett 2003; 225: 195-200.
110. Trinh S, Reysset G. Detection by PCR of the nim genes encoding 5-nitroimidazole resistance in Bacteroides spp. J Clin Microbiol 1996; 34: 2078-84.
111. Lubbe MM, Stanley K, Chalkley LJ. Prevalence of nim genes in anaerobic/facultative anaerobic bacteria isolated in South Africa. FEMS Microbiol Lett 1999; 172: 79-83.
112. Carlier JP, Sellier N, Rager MN, Reysset G. Metabolism of a 5-nitroimidazole in susceptible and resistant isogenic strains of Bacteroides fragilis. Antimicrob Agents Chemother 1997; 41: 1495-9.
113. Mendz GL, Trend MA. Intracellular redox status and antibiotic resistance in enterogastric micro-aerophilic bacteria: evidence for the 'scavenging of oxygen' hypothesis. Redox Rep 2001; 6: 179-81.
114. Lim, A, Eleuterio M, Hutter B, Murugasu-Oei B, Dick T. Oxygen depletion-induced dormancy in Mycobacterium bovis BCG. J Bacteriol 1999; 181: 2252-6.
115. Murugasu-Oei B, Dick, T. Bactericidal activity of nitrofurans against growing and dormant Mycobacterium bovis BCG. J Antimicrob Chemother 2000; 46: 917-9.
116. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537-44.
117. Bair TB, Isabelle DW, Daniels L. Structures of coenzyme F(420) in Mycobacterium species. Arch Microbiol 2001; 176: 37-43.
118. Choi KP, Kendrick N, Daniels L. Demonstration that fbiC is required by Mycobacterium bovis BCG for coenzyme F(420) and FO biosynthesis. J Bacteriol 2002; 184: 2420-8.
119. Rafii F, Hehman G, Lunsford P. Purification and characterization of an enzyme from Mycobacterium sp. Pyr-1, with nitroreductase activity and an N-terminal sequence similar to lipoamide dehydrogenase. Arch Microbiol 2001; 176: 381-5.
120. Zhang Z, Hillas PJ, Ortiz de Montellano PR. Reduction of peroxides and dinitrobenzenes by Mycobacterium tuberculosis thioredoxin and thioredoxin reductase. Arch Biochem Biophys 1999; 363: 19-26.
121. Purkayastha A, McCue LA, McDonough KA. Identification of a Mycobacterium tuberculosis putative classical nitroreductase gene whose expression is coregulated with that of the acr aene within macrophages, in standing versus shaking cultures, and under low oxygen conditions. Infect Immun 2002; 70: 1518-29.
122. Crossnoe CR, Germanas JP, LeMagueres P, Mustata G, Krause KL. The crystal structure of Trichomonas vaginalis ferredoxin provides insight into metronidazole activation. J Mol Biol 2002; 318: 503-18.
123. Hu Y, Butcher PD, Mangan JA, Rajandream MA, Coates AR. Regulation of hmp gene transcription in Mycobacterium tuberculosis: effects of oxygen limitation and nitrosative and oxidative stress. J Bacteriol 1999; 181: 3486-93.
124. Gillis JC, Wiseman LR. Secnidazole. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis. Drugs 1996; 51: 621-38.
125. Bergan T. Antibacterial activity and pharmacokinetics of nitroimidazoles. A review. Scand J Infect Dis Suppl 1985; 46: 64-71.
126. Bone W, Jones AR, Cooper TG. The effect of (R, S)-ornidazole on the fertility of male mice and the excretion and metabolism of 36Cl-(R, S)-ornidazole and 36Cl-(R, S)-alpha-chlorohydrin in male mice and rats. Int J Androl 2002; 25: 94-9.
127. Stambaugh JE, Feo LG, Manthei RW. The isolation and identification of the urinary oxidative metabolites of metronidazole in man. J Pharmacol Exp Ther 1968; 161: 373-81.
128. Muscara MN, Pedrazzoli J Jr, Miranda EL, Ferraz JG, Hofstatter E, Leite G, et al. Plasma hydroxy-metronidazole/metronidazole ratio in patients with liver disease and in healthy volunteers. Br J Clin Pharmacol 1995; 40: 477-80.
129. Chasseaud LF, Henrick K, Matthews RW, Scott PW, Wood SG. Metabolic Ring Hydroxylation of Tinidazole involving a Novel Nitro-group Migration: X-Ray Structures of Tinidazole and the NH4+ Salt of its Ring Hydroxylated Metabolite. J Chem Soc Chem Commun 1984; 8: 491-492.
130. Jones AR, Cooper TG. Metabolism of 36Cl-ornidazole after oral application to the male rat in relation to its antifertility activity. Xenobiotica 1997; 27: 711-21.
131. O'Keefe JP, Troc KA, Thompson KD. Activity of metronidazole and its hydroxy and acid metabolites against clinical isolates of anaerobic bacteria. Antimicrob Agents Chemother 1982, 22: 426-30.
132. Bannatyne RM. Metronidazole, its bioactive metabolites and acne. Curr Med Res Opin 1999; 15: 298-9.
133. Roe FJ. Toxicologic evaluation of metronidazole with particular reference to carcinogenic, mutagenic, and teratogenic potential. Surgery 1983; 93: 158-64.
134. Roe FJ. Safety of nitroimidazoles. Scand J Infect Dis Suppl 1985; 46: 72-81.
135. Cooper TG, Yeung CH, Skupin R, Haufe G. Antifertility potential of ornidazole analogues in rats. J Androl 1997; 18: 431-8.
136. Bone W, Yeung CH, Skupin R, Haufe G, Cooper TG. Toxicity of ornidazole and its analogues to rat spermatozoa as reflected in motility parameters. Int J Androl 1997; 20: 347-55.
137. Linder RE, Strader LF, Slott VL, Suarez JD. Endpoints of spermatotoxicity in the rat after short duration exposures to fourteen reproductive toxicants. Reprod Toxicol 1992; 6: 491-505.
138. McClain RM, Downing JC. Reproduction studies in rats treated with ornidazole. Toxicol Appl Pharmacol 1988; 92: 480-7.
139. McClain RM, Downing JC. The effect of ornidazole on fertility and epididymal sperm function in rats. Toxicol Appl Pharmacol 1988; 92: 488-96.
140. Vidakovic M, Crossnoe CR, Neidre C, Kim K, Krause KL, Germanas JP. Reactivity of reduced [2Fe-2S] ferredoxins parallels host susceptibility to nitroimidazoles. Antimicrob Agents Chemother 2003; 47: 302-8.
141. Purohit V, Basu A. Mutagenicity of Nitroaromatic Compounds. Chem Res Toxicol 2000; 13: 673-692.
142. Carroll CC, Warnakulasuriyarachchi D, Nokhbeh MR, Lambert IB. Salmonella typhimurium mutagenicity tester strains that overexpress oxygen-insensitive nitroreductases nfsA and nfsB. Mutat Res 2002; 501: 79-98.
143. De Meo M, Vanelle P, Bernadini E, Laget M, Maldonado J, Jentzer O, et al. Evaluation of the mutagenic and genotoxic activities of 48 nitroimidazoles and related imidazole derivatives by the Ames test and the SOS chromotest. Environ Mol Mutagen 1992; 19: 167-81.
144. Voogd CE, van der Stel JJ, Jacobs JJ. The mutagenic action of nitroimidazoles. IV. A comparison of the mutagenic action of several nitroimidazoles and some imidazoles. Mutat Res 1979; 66: 207-21.
145. Debnath AK, Lopez de Compadre RL, Debnath G, Shusterman AJ, Hansch C. Structure-activity relationship of mutagenic aromatic and heteroaromatic nitro compounds. Correlation with molecular orbital energies and hydrophobicity. J Med Chem 1991; 34: 786-97.
146. Walsh JS, Wang R, Bagan E, Wang CC, Wislocki P, Miwa GT. Structural alterations that differentially affect the mutagenic and antitrichomonal activities of 5-nitroimidazoles. J Med Chem 1987; 30: 150-6.
147. Connor TH, Stoeckel M, Evrard J, Legator MS. The contribution of metronidazole and two metabolites to the mutagenic activity detected in urine of treated humans and mice. Cancer Res 1977; 37: 629-33.
148. Speck WT, Stein AB, Rosenkranz HS. Mutagenicity of metronidazole: presence of several active metabolites in human urine. J Natl Cancer Inst 1976; 56: 283-4.
149. Lopez Nigro MM, Palermo AM, Mudry MD, Carballo MA Cytogenetic evaluation of two nitroimidazole derivatives. Toxicol In vitro 2003; 17: 35-40.
150. Rodriguez Ferreiro G, Cancino Badias L, Lopez-Nigro M, Palermo A, Mudry M, Gonzalez Elio P, et al. DNA single strand breaks in peripheral blood lymphocytes induced by three nitroimidazole derivatives. Toxicol Lett 2002; 132: 109-15.
151. Lopez Nigro MM, Gadano AB, Carballo MA. Evaluation of genetic damage induced by a nitroimidazole derivative in human lymphocytes: Tinidazole (TNZ). Toxicol In vitro 2001; 15: 209-13.
152. Martelli A, Allavena A, Robbiano L, Mattioli F, Brambilla G. Comparison of the sensitivity of human and rat hepatocytes to the genotoxic effects of metronidazole. Pharmacol Toxicol 1990; 66: 329-34.
153. Dayan J, Crajer MC, Deguingand S. Mutagenic activity of 4 active-principle forms of pharmaceutical drugs. Comparative study in the Salmonella typhimurium microsome test, and the HGPRT and Na+/K+ ATPase systems in cultured mammalian cells. Mutat Res 1982; 102: 1-12.
154. Menendez D, Bendesky A, Rojas E, Salamanca F, Ostrosky-Wegman P. Role of P53 functionality in the genotoxicity of metronidazole and its hydroxy metabolite. Mutat Res 2002; 501: 57-67.
155. Ostrosky-Wegman P, Asseff IL, Santiago P, Elizondo G, Montero R. Metronidazole hprt mutation induction in sheep and the relationship with its elimination rate. Mutat Res 1994; 307: 253-9.
156. Teixeira AR, Cordoba JC, Souto Maior I, Solorzano E. Chagas' disease: lymphoma growth in rabbits treated with Benznidazole. Am J Trop Med Hyg 1990; 43: 146-58.
157. Teixeira AR, Calixto MA, Teixeira ML. Chagas' disease: carcinogenic activity of the antitrypanosomal nitroarenes in mice. Mutat Res 1994; 305: 189-96.
158. Mitelman F, Hartley-Asp B, Ursing B. Chromosome aberrations and metronidazole. Lancet 1976; 2: 802.
159. Mitelman F, Strombeck B, Ursing B. No cytogenic effect of metronidazole. Lancet 1980; 1: 1249-50.
160. Mitelman F, Strombeck B, Ursing B, Nordle O, Hartley-Asp B. Metronidazole exhibits no clastogenic activity in a double-blind cross-over study on Crohn's patients. Hereditas 1982; 96: 279-86.
161. Elizondo G, Gonsebatt ME, Salazar AM, Lares I, Santiago P, Herrera J, et al. Genotoxic effects of metronidazole. Mutat Res 1996; 370: 75-80.
162. Menendez D, Rojas E, Herrera LA, Lopez MC, Sordo M, Elizondo G, et al. DNA breakage due to metronidazole treatment. Mutat Res 2001; 478: 153-8.
163. Salamanca-Gomez F, Castaneda G, Farfan J, Del C, Santillan M, Munoz O, et al. Chromosome studies of bone marrow cells from metronidazole-treated patients. Ann Genet 1980; 23: 63-4.
164. Reitz M, Rumpf M, Knitza R. DNA single strand-breaks in lymphocytes after metronidazole therapy. Arzneimittelforschung 1991; 41: 155-6.
165. Fahrig R, Engelke M. Reinvestigation of in vivo genotoxicity studies in man. I. No induction of DNA strand breaks in peripheral lymphocytes after metronidazole therapy. Mutat Res 1997; 395: 215-21.
166. Rustia M, Shubik P. Experimental induction of hepatomas, mammary tumors, and other tumors with metronidazole in noninbred Sas:MRC(WI)BR rats. J Natl Cancer Inst 1979; 63: 863-8.
167. Cavaliere A, Bacci M, Vitali R. Induction of mammary tumors with metronidazole in female Sprague-Dawley rats. Tumori 1984; 70: 307-11.
168. Beard CM, Noller KL, O'Fallon WM, Kurland LT, Dockerty MB. Lack of evidence for cancer due to use of metronidazole. N Engl J Med 1979; 301: 519-22.
169. Beard CM, Noller KL, O'Fallon WM, Kurland LT, Dahlin DC. Cancer after exposure to metronidazole. Mayo Clin Proc 1988; 63: 147-53.
170. Friedman GD. Cancer after metronidazole. N Engl J Med 1980; 302: 519.
171. Danielson DA, Hannan MT, Jick H. Metronidazole and cancer. JAMA 1982; 247: 2498-9.
172. Falagas ME, Walker AM, Jick H, Ruthazer R, Griffith J, Snydman DR. Late incidence of cancer after metronidazole use: a matched metronidazole user/nonuser study. Clin Infect Dis 1998; 26: 384-8.
173. Thapa PB, Whitlock JA, Brockman Worrell KG, Gideon P, Mitchel EF Jr, Roberson P, et al. Prenatal exposure to metronidazole and risk of childhood cancer: a retrospective cohort study of children younger than 5 years. Cancer 1998; 83: 1461-8.
174. Diav-Citrin O, Shechtman S, Gotteiner T, Arnon J, Ornoy A. Pregnancy outcome after gestational exposure to metronidazole: a prospective controlled cohort study. Teratology 2001; 63: 186-92.
175. Morgan I. Metronidazole treatment in pregnancy. Int J Gynaecol Obstet 1978; 15: 501-2.
176. Denny WA. Nitroreductase-based GDEPT. Curr Pharm Design 2002; 8(15): 1349-61.
177. Urbina JA. Chemotherapy of Chagas disease. Curr Pharm Design 2002; 8(4): 287-95.
178. Yanagihara K. Design of anti-bacterial drug and anti-mycobacterial drug for drug delivery system. Curr Pharm Design 2002; 8(6): 475-82.